Biohaven Pharmaceutical Holding Company (NYSE:BHVN) announces that a Phase 3 clinical trial
evaluating troriluzole as monotherapy in patients with generalized
anxiety disorder (GAD) failed to sufficiently separate from placebo on
the primary endpoint of total HAM-A score at week 8.
The company will terminate development for
monotherapy use in GAD. Several studies in other diseases and with
different dosing approaches are in process.
The company says troriluzole is a third-generation
prodrug that modulates an excitatory neurotransmitter called glutamate
by reducing its levels at nerve synapses.
Shares down 17% premarket on average volume.
https://seekingalpha.com/news/3539972-biohaven-down-17-premarket-on-failed-troriluzole-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.